Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: Implications for neuroprotective strategies

Experimental Neurology

Volumn 147, Issue 1, 1997, Pages 115-122

  Stefani, A ^a,b   Spadoni, F ^a,b   Bernardi, G ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; LAMOTRIGINE; PHENYTOIN; RILUZOLE;

ANIMAL CELL; ARTICLE; BRAIN CELL; CALCIUM CURRENT; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; MALE; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM CONDUCTANCE; SODIUM CURRENT;

EID: 0031239776     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6554     Document Type: Article

References (54)

1. Albin R. L., Greenamyre J. T. Alternative excitotoxic hypothesis. Neurology. 42:1992;733-788.
2. Beal M. F. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
3. Benoit E., Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibres. Pfluegers Arch. 419:1991;603-609.
4. Bensimon G., Lacomblez L., Meininger V., Group A. R. S. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330:1994;585-591.
5. Brouillet E., Hyman B. T., Jenkins B. G., Henshaw D. R., Schulz J. B., Sodhi P., Rosen B. R., Beal M. F. Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. Exp. Neurol. 129:1994;175-182.
6. Calabresi P., Stefani A., DeMurtas M., Pisani A., Sancesario G., Bernardi G. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia. 336:1995;990-996.
7. Calabresi A., Siniscalchi A., Pisani A., Stefani A., Mercuri N. B., Bernardi G. A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Neurology. 47:1996;557-562.
8. Choi D., Rothman S. M. The role of glutamate neurotoxicity in hypoxic-hischemic neuronal death. Annu. Rev. Neurosci. 13:1991;171-182.
9. Coulter D. A., Huguenard J. R., Prince D. A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann. Neurol. 25:1989;582-593.
10. Coyle J. T., Puttfarcken P. Oxidative stress, glutamate and neurodegenerative disorders. Science. 262:1993;689-695.
11. Frandsen A., Schousboe A. Excitatory amino-acid-mediated cytotoxicity and calcium homeostasis in cultured neurons. J. Neurochem. 60:1993;1202-1211.
12. Giroux C., Scatton B. Ischemic stroke: Treatment on the horizon. Exp. Neurol. 36:1996;61-64.
13. Graham S. H., Chen J., Sharp F. R., Simon R. P. Limiting ischemic injury by inhibition of excitatory amino acid release. J. Cereb. Blood Flow Metab. 13:1993;88-97.
14. Greene J. G., Greenamyre J. T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48:1996;613-634.
15. Gurney M. E., Cuttings F. B., Zhai P., Doble A., Taylor C. P., Andrus P. K., Hall E. D. Benefit of vitamin E, Riluzole, and Gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39:1996;147-157.
16. Hamill O. P., Marty A., Neher E., Sakmann B., Sigworth F. J. Improved patch-clamp techniques for high-resolution current recoding from cell and cell-free membrane patches. Pfluegers Arch. 391:1981;85-100.
17. Hayakawa T., Hamada J., Maihara T., Hattori H., Mikawa H. Phenytoin reduces neonatal hypoxic-hischemic brain damage in rats. Life Sci. 54:1994;387-392.
18. Hebert T., Drapeau P., Pradier L., Dunn R. J. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol. Pharmacol. 45:1994;1055-1060.
19. Koroshetz W. J., Moskowitz M. A. Emerging treatments for stroke in humans. Trends Pharmacol. Sci. 17:1996;227-233.
20. Ikonomodou C., Turski L. Excitotoxicity and neurodegenerative diseases. Curr. Opin. Neurol. 8:1995;487-497.
21. Lang D. G., Wang C. M., Cooper B. R. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J. Pharmacol. Exp. Ther. 266:1993;829-835.
22. Leach M. J., Baxter M. G., Critchley M. A. Neurochemical and behavioral aspects of lamotrigine. Epilepsia. 32:1996;S4-S8.
23. Lipton S. A., Rosenberg P. A. Excitatory amino acids as a common pathway for neurologic disorders. N. Engl. J. Med. 330:1994;613-622.
24. Lorenzon N. M., Foehring R. C. Characterization of pharmacologically identified voltage-gated calcium channel currents in acutely isolated neocortical neurons. I. Adult neurons. J. Neurophysiol. 73:1995;1430-1441.
25. MacDonald R. L., Kelly K. M. Antiepileptic drug mechanisms of action. Epilepsia. 34:1993;S1-S8.
26. 2+. Mol. Pharmacol. 36:1989;106-112.
27. Martin D., Thompson M. A., Nadler J. D. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 250:1993;473-476.
28. McLean M. J., MacDonald R. L. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J. Pharmacol. Exp. Ther. 227:1983;779-789.
29. Meldrum B. S. The role of glutamate in epilepsy and other CS disorders. Neurology. 44:1994;S14-S23.
30. Mizoule J., Meldrum B., Mazadier M., Croicher M., Ollat C., Uzan A., Legrand J. J., Gueremy C., Le Fur G. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid transmission. I. Anticonvulsant properties. Neuropharmacology. 24:1985;767.
31. Muir K. W., Lees K. R., Hamilton S. J. C., George C. F. Tolerability and safety of 619C89 in acute stroke. Stroke. 26:1995;157.
32. Narahashi, et al. 1996, Soc. Neurosci. Abstr. 690.8.
33. Pellegrini-Giampietro D. E., Cherici G., Alesiani A., Moroni F. Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J. Neurosci. 10:1990;1035-1041.
34. Pratt J., Rataud J., Bardot F., Roux M., Blanchard J.-M., Laduron P. M., Stutzmann J. M. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci. Lett. 140:1992;225-230.
35. Rothstein J. D., Kunel R. W. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J. Neurochem. 65:1995;643-651.
36. Sayer R. J., Schwindt P. C., Crill W. E. High- and low-threshold calcium currents in neurons acutely isolated from rat sensorimotor cortex. Neurosci. Lett. 120:1990;175-178.
37. Schulz J. B., Matthews R. T., Henshaw D. R., Beal M. F. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases. Neuroscience. 71:1996;1043-1048.
38. Siesjo B. K., Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: A unifying hypothesis. J. Cereb. Blood Flow Metab. 9:1989;127-140.
39. Siniscalchi A., Bonci A., Mercuri N. B., Bernardi G. Effect of riluzole on rat cortical neurons: An in vitro electrophysiological study. Br. J. Pharmacol. 120:1997;225-230.
40. Smith S. E., Meldrum B. S., Chir M. B. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke. 26:1995;117-121.
41. Stefani A., Calabresi P., Pisani A., Mercuri N. B., Siniscalchi A., Bernardi G. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J. Pharmacol. Exp. Ther. 277:1996;121-129.
42. Stefani A., Spadoni F., Bernardi G. High-voltage-activated calcium channels: Target of antiepileptic drug therapy? Epilepsia. 1996.
43. Stefani A., Pisani A., De Murtas M., Mercuri N. B., Marciani M. G., Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II Modulation of high-voltage-activated calcium currents. Epilepsia. 336:1995;997-1002.
44. 2+. Eur. J. Pharmacol. 307:1996;113-116.
45. +. J. Neurosci. 16:1996;5004-5013.
46. Takahashi T., Momiyama A. Different types of calcium channels mediate central synaptic transmission. Nature. 366:1993;156-158.
47. +. Trends Pharmacol. Sci. 16:1995;309-316.
48. Tymianski M., Tator C. H. Normal and abnormal calcium homeostasis in neurons: A basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery. 38:1996;1176-1195.
49. Umemija M., Berger A. J. Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal mùotoneurones. Br. J. Pharmacol. 16:1995;3227-3230.
50. Wakamori M., Kaneda M., Oyama J., Akaike N. Effects of chlordiazepoxide, chlorpromazine, diazepam, diphenylhydantoin, fluniutrazepam, and haloperodl on the voltage-dependent sodium current of isolated brain neurons. Brain Res. 494:1989;374-378.
51. Waldmeier P. C., Baumann P. A., Wicki P., Feldatraurer J-J., Stierlin C., Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology. 45:1995;1907-1913.
52. Whetsell W. O. Jr. Current concepts of excitotoxicity. J. Neuropathol. Exp. Neurol. 55:1996;1-12.
53. ++. Neuroscience. 73:1996;951-962.
54. ++. Pfluegers Arch. Eur. J. Physiol. 430:1995;437-446.